U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Description

Нeparin (or Unfractionated heparin ) is an anticoagulant indicated for both the prevention and treatment of thrombotic events such as deep vein thrombosis (DVT) and pulmonary embolism (PE) as well as atrial fibrillation (AF). Heparin can also be used to prevent excess coagulation during procedures such as cardiac surgery, extracorporeal circulation or dialysis, including continuous renal replacement therapy. Heparin administration can be by intravenous (or subcutaneous route. Intravenous heparin is continuously administered for therapeutic anticoagulation, while intermittent subcutaneous administration is used to prevent thromboembolism. Once administered, heparin binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. The heparin-ATIII complex can also inactivate factors IX, XI, XII, and plasmin, but the antithrombotic effect of heparin is well correlated to the inhibition of factor Xa. Typical adverse effects from heparin use include bleeding, thrombocytopenia, injection site reactions, and other adverse effects only seen with chronic heparin administration. Bleeding is a major complication associated with heparin use. Patients should undergo monitoring for new bleeding that may present in the urine or stool. Bleeding may also present as bruising, petechial rash and nosebleeds.

CNS Activity

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
106.0 nM [Kd]
607.0 nM [Kd]
281.0 nM [Kd]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
HEPARIN SODIUM
Primary
HEPARIN SODIUM
Primary
HEPARIN SODIUM
PubMed

PubMed

TitleDatePubMed

Sample Use Guides

In Vivo Use Guide
Deep Subcutaneous (Intrafat) Injection: Initial -- 5,000 units by intravenous injection, followed by 10,000 units to 20,000 units of a concentrated solution Every 8 hours: 8,000 units to 10,000 units of a concentrated solution Intermittent Intravenous Injection: Initial: 10,000 units, either undiluted or in 50 mL to 100 mL of 0.9% Sodium Chloride Injection, USP by intravenous injection Every 4 to 6 hours: 5,000 units to 10,000 units, either undiluted or in 50 mL to 100 mL of 0.9% Sodium Chloride Injection, USP
Route of Administration: Intravenous; Subcutaneous
Name Type Language
HEPARIN
HSDB   INCI   MART.   VANDF   WHO-DD  
INCI  
Official Name English
HEPARIN [VANDF]
Common Name English
HEPARIN [HSDB]
Common Name English
SULPHATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS
Common Name English
HEPARIN [INCI]
Common Name English
HEPARIN, PORCINE
Common Name English
HEPARIN [MART.]
Common Name English
HEPARIN [WHO-DD]
Common Name English
HEPARIN PORCINE INTESTINAL MUCOSA
Common Name English
SULFATED GLYCOSAMINOGLYCANS PRESENT AS A MIXTURE OF HETEROGENEOUS MOLECULES VARYING IN MOLECULAR WEIGHTS
Common Name English
Classification Tree Code System Code
WHO-ATC B01AB01
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
FDA ORPHAN DRUG 178103
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-VATC QC05BA03
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
NCI_THESAURUS C263
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-ATC B01AB51
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
FDA ORPHAN DRUG 211305
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
NDF-RT N0000006341
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-ATC C05BA03
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-ATC C05BA53
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-ATC S01XA14
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
LIVERTOX 479
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
NDF-RT N0000175474
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-ATC B01AB12
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-VATC QB01AB51
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-VATC QB01AB01
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
WHO-VATC QS01XA14
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
NDF-RT N0000175980
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
Code System Code Type Description
EVMPD
SUB02475MIG
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
RXCUI
5224
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
CAS
9005-49-6
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
MESH
D006493
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
ECHA (EC/EINECS)
232-681-7
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
NCI_THESAURUS
C539
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
WIKIPEDIA
HEPARIN
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
RXCUI
235473
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
ALTERNATIVE
DRUG BANK
DB01109
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
IUPHAR
4214
Created by admin on Tue Oct 22 00:45:19 UTC 2019 , Edited by admin on Tue Oct 22 00:45:19 UTC 2019
PRIMARY
Display Structure of HEPARIN